18:03 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
21:33 , Sep 26, 2018 |  BC Extra  |  Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
19:29 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy Extension and chemical modification of the 5’ end of CRISPR RNAs (crRNAs) could enhance the editing efficiency and serum stability of CRISPR-Cas12a-based gene therapies. The method involves modifying crRNAs at the 5’...
22:19 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Public Funding Highlights: 2Q18

Public Funding Highlights: 2Q18...
00:00 , Apr 20, 2018 |  BC Innovations  |  Tools & Techniques

Structured outlook

A...
18:15 , Feb 28, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice deficient in AAT paralogs could be used to screen therapies for AAT deficiency-induced emphysema. In mice, knockout of all five paralogs of human AAT recapitulated the poor elastic resistance and...
16:26 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Arrowhead raises $60.4M follow-on

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) raised $60.4 million through the sale of 11.5 million shares at $5.25 in a follow-on, including a 1.5 million share overallotment, on Jan. 22. Jefferies, Barclays Capital, Cantor Fitzgerald, Chardan...
22:52 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Adverum begins Phase I/II of ADVM-043 for AAT deficiency

Adverum Biotechnologies Inc. (NASDAQ:ADVM) began the Phase I/II ADVANCE trial to evaluate ADVM-043 in up to 20 patients with alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The study will enroll up to four cohorts, with the...
01:09 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest gene therapies delivering secretion-optimized GAA variants could help treat Pompe’s disease. The gene therapies consist of a liver-tropic adeno-associated viral serotype 8 (AAV8) vector encoding one of two GAA...